|Bid||13.67 x 800|
|Ask||13.69 x 800|
|Day's Range||13.29 - 13.81|
|52 Week Range||12.68 - 23.05|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 7, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.50|
Codexis, Inc. , a leading protein engineering company, is contributing resources and expertise to communicate protein engineering’s vast potential at SynBioBeta’s Global Synthetic Biology Summit in San Francisco, Oct.
REDWOOD CITY, Calif., Sept. 26, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the 2019 Cantor.
President and CEO of Codexis Inc (30-Year Financial, Insider Trades) John J Nicols (insider trades) bought 10,000 shares of CDXS on 08/20/2019 at an average price of $13.3 a share. Continue reading...
Codexis (CDXS) delivered earnings and revenue surprises of -100.00% and -17.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Product revenue up 68%; R&D revenue spread over wider base of customers and markets Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif., Aug. 06,.
REDWOOD CITY, Calif., July 30, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results.
Codexis, Inc. (CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement. “The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets,” said Codexis President and CEO John Nicols.
REDWOOD CITY, Calif., May 30, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at the Jefferies 2019 Global.
Codexis, Inc. (CDXS), a leading protein engineering company, announces the signing of a CodeEvolver® platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license to its proprietary CodeEvolver® protein engineering platform technology to Novartis to develop novel performance enzymes for use in manufacturing pharmaceutical products. Upon completion of the technology transfer, the CodeEvolver® protein engineering platform will be located at a Novartis site.
REDWOOD CITY, Calif., May 14, 2019 -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in three upcoming.
The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 5.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Redwood City, California-based company said it had a loss of 9 cents per share. Losses, adjusted for stock option expense and non-recurring costs, came to 5 cents per share. The producer of custom ...
Total revenues increase 11% to $15.6 million, product revenue up 30% Recent highlights include Third CodeEvolver® Platform Technology Agreement and Multi-Year Enzyme Supply and.